Placeholder Banner

BIO Comments to CMS on the Proposed Rule Dealing with Medicare Drug Pricing

February 13, 2023

BIO’s comments on specific aspects of CMS’s Proposed Rule on Medicaid drug pricing are presented below.

Download Full Comments Below
BIO Comment for CY 2024 MA and Part D.pdf
Discover More
To protect patient access to critical prescription drugs, BIO has identified Part D guardrails (both MA-PD and PDP) for consideration as CMS develops guidance to plans for CY2025 and beyond.
On behalf of CSBA, BIO submitted this MDRP sign-on letter to CMS, which strongly urged the agency to refrain from finalizing a proposal that would drastically impact the Medicaid Best Price calculation.
BIO submitted comments to CMS per their Notice of Proposed Rulemaking: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.